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Stroke (focal cerebral ischemia) is a leading cause of death and disability among adult population. Many pathological events
including inﬂammation and oxidative stress during the acute period contributes to the secondary neuronal death leading the
neurological dysfunction after stroke. Transcriptional regulation of genes that promote these pathophysiological mechanisms can
beaneﬀectivestrategytominimizethepoststrokeneuronaldeath.Peroxisomeproliferator-activatedreceptors(PPARs)areligand-
activated transcription factors known to be upstream to many inﬂammatory and antioxidant genes. The goal of this review is to
discuss the therapeutic potential and putative mechanisms of neuroprotection following PPAR activation after stroke.
Copyright © 2008 Raghu Vemuganti . This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1. PEROXISOME PROLIFERATOR-ACTIVATED
RECEPTOR (PPAR)
PPAR and retinoid X receptor (RXR) are ligand-activated
transcription factors of the nuclear hormone receptor super-
family [1, 2]. PPAR exists as 3 isoforms (α, γ,a n dδ/β)w i t h
distinct natural agonists for each isoform. RXR also exists
as 3 isoforms (α, β,a n dγ), but all 3 can be activated by
common ligands [3]. Both RXR and PPAR are composed
of a ligand binding domain (LBD) and a DNAbinding
domain (DBD) [4]. When their respective ligands bind to
PPAR and RXR, they form a heterodimeric complex which
recruits other coactivators including PPAR coactivator-1 and
-2, PPAR-binding protein, PPAR-interacting protein, CREB-
binding protein and steroid receptor coactivator-1. This
complex binds to the promoter regions of speciﬁc genes
that contain a regulatory element known as the peroxisome
proliferator response element (PPRE; AGGTCA-AGGTCA
repeats) which either activates or transrepresses the target
genes [1, 5]. Binding of a speciﬁc agonist to PPAR is a
prerequisite for coactivator binding. In the absence of a
ligand, the PPARγ:RXR complex can recruit corepressor
complexes and bind to PPRE, suppressing the transcription
of target genes [6]. Thus PPARs can control the gene
expression positively as well as negatively.
2. FUNCTIONAL SIGNIFICANCE OF PPARs
In the mammalian body, PPARs control glucose and lipid
metabolism, cell proliferation and diﬀerentiation [1, 7].
In particular, the PPARγ isoform behaves as a “molecular
sensor,” binding a wide range of molecules involved in
metabolism, and has been studied extensively in diabetes
and obesity due to its role in regulating glucose metabolism
[8, 9]. A class of synthetic, insulin-sensitizing compounds
called thiazolidinediones (TZDs) have emerged as potent,
exogenous agonists of PPARγ and are being prescribed for
type-2 diabetes [1, 10]. PPARγ shows a highly restricted
pattern of expression. It is present at a high amount in
adipose tissue where it regulates adipocyte diﬀerentiation
and lipid metabolism [5]. Its expression is also very high in
cells of the immune system such as monocytes/macrophages,
B and T cells [11]. In the normal adult brain, PPARγ shows
a relatively low level of expression primarily limited to the
granule cells of the hippocampal dentate gyrus [11]. Some
PPARγ expression is also present in the caudate putamen
and globus pallidus of the basal ganglia, thalamus, and the
piriform cortex [2]. Recent studies indicated that microglia
and astrocytes, the cell types that play a signiﬁcant role in
theinﬂammatoryresponsesoftheCNSshowhighexpression
levels of PPARγ [12]. More recently, several TZDs including2 PPAR Research
the United States Food and Drug Administration (FDA)
approved rosiglitazone and pioglitazone were shown to
control inﬂammation in peripheral organs as well as CNS
[13, 14].
3. PPAR LIGANDS
The endogenous agonists of PPARα include eicosinoids-
like leukotriene B4 and 8(S)-hydroxy-eicosatetraenoic
acid [15]. Whereas 15-deoxy-delta-12,14-prostaglandin-J2
(15dPGJ2), and several oxidized metabolites of hydroxyl-
eicosatetraenoic acid and hydroxyl-eicosadecaenoic acid
are the natural ligands for PPARγ [16]. Many prostanoids
are the natural ligands for PPARδ/β [17]. The 3 RXR
isoforms use common ligands that include 9-cis retinoic
acid, docosahexaenoic acid, and phytanic acid [3].
4. PROMOTERS OF STROKE-INDUCED
BRAIN DAMAGE
Following stroke, while the ischemic core undergoes irre-
versible damage, the penumbra (tissue surrounding the
core) can potentially be rescued with timely therapeutic
intervention [18]. Typically, the penumbra is much larger
in volume than the core to start with, but as the cell death
progresses with time, the infarct grows in size engulﬁng
penumbra [19]. The secondary neuronal death that even-
tually precipitates the long-term neurological dysfunction
after stroke is caused by many synergistic pathophysiological
mechanisms involving various cell types. In particular,
massive inﬂammation that starts immediately and continues
for days after focal ischemia is a major promoter of ischemic
neuronal death [20]. In core of injury, anoxic depolar-
ization promotes calcium and potassium release leading
to neurotransmitter glutamate release. This follows with
a wave of spreading depression which promotes further
glutamate release in penumbra. Increased extracellular glu-
tamate promotes excitotoxic secondary neuronal death in
core as well as penumbra. Immediately after stroke, due to
lack of oxygen and glucose, the ionic gradients across cell
membranes collapse leading to water inﬂux and edema in
CNS.Inaddition,mitochondrialfailureleadstoendoplasmic
reticulum (ER) stress and oxidative stress. This is followed
by the increased expression of inﬂammatory genes and
inﬁltration of leukocytes into brain parenchyma. All these
pathophysiological events are thought to synergistically
promote the postischemic neuronal death [21].
5. INFLAMMATION AFTER STROKE
In a normal brain, the blood-brain barrier (BBB) controls
the inﬁltration of white blood cells into brain parenchyma.
However, following ischemia induction of the adhesion
molecules like intercellular adhesion molecule-1 (ICAM1),
E-selectin, and P-selectin on the endothelial cells promotes
leukocyte adherence and extravasation [20]. The inﬁltrated
macrophages and neutrophils activate resident microglia
and astrocytes [22]. Following stroke, leukocytes as well as
neurons, astrocytes, microglia, and oligodendrocytes gen-
erate proinﬂammatory mediators including cytokines like
interleukin (IL)-6 and IL-1β, chemokines like macrophage
inﬂammatory protein-1α and monocyte chemoattractant
protein-1 (MCP1), prostaglandins and free radicals which
exacerbate postischemic secondary neuronal death [23, 24].
6. ROLE OF TRANSCRIPTION FACTORS IN
POSTISCHEMIC INFLAMMATION
Transcription factors play a central role in modulating
inﬂammation by controlling the expression of cytokines,
chemokines, and other inﬂammatory genes. Ischemia is a
known stimulator of many transcription factors including
hypoxia inducible factor-1 (HIF1), signal transducer and
activator of transcription-3 (STAT3), early growth response-
1 (Egr1), nuclear factor (erythroid-derived 2)-like 2 (Nrf2),
interferon regulatory factor-1 (IRF1), activating transcrip-
tion factor-3 (ATF3), cAMP response element binding pro-
tein (CREB), cAMP response element modulator (CREM),
and nuclear factor-kappa B (NF-κB) that are known to
be signiﬁcantly modulate the postischemic inﬂammatory
gene expression [25–28]. While the transcription factors like
STAT3, IRF1, C/EBPβ,N F - κB, ATF3, and EGR1 promote
neuronal damage by inducing inﬂammatory genes [26–
31], transcription factors like HIF1, Nrf2, PPARα,P P A R γ,
and CREBare thought to be beneﬁcial as they curtail the
expression of genes that promote either inﬂammation or
oxidative stress [32–36]. Drugs that target transcription
factors could be eﬀective as they act upstream to gene
expression, thus curtailing the inﬂammation and other
destructive pathways.
7. ANTI-INFLAMMATORY EFFECTS OF PPARγ
ACTIVATION IN THE PERIPHERAL ORGANS
Many recent studies demonstrated that PPARγ agonists
exert signiﬁcant protection in various animal models of
neurological and cardiovascular disorders [37–40]. Activated
macrophages release proinﬂammatory cytokines such as
tumor necrosis factor-α (TNFα) and IL6 and free radicals
such as nitric oxide (NO) and superoxide. PPARγ activation
by its agonists was shown to inhibit the expression of
inducible NO synthase (iNOS) and inﬂammatory cytokine
production in macrophages and endothelial cells [5, 41, 42].
PPARγ agonists were also shown to reduce ROSformation in
coronary artery endothelial cells and cardiac ﬁbroblasts [43,
44]. Pioglitazone was shown to curtail ICAM1 and MCP1
expressionleadingtodecreasedmacrophageinﬁltrationafter
cardiac ischemia leading to curtailed myocardial damage
in rats [45]. PPARγ natural ligand 15dPGJ2 was shown
to prevent the expression of IL6, IL1β,a n dT N F α in
phorbol 12-myristate 13-acetate-stimulated monocytes [42].
The systemic inﬂammation in joints of rheumatoid arthritis
patients and in the pancreas of diabetics was also shown
to be minimized by treatment of PPARγ agonists [8, 46–
48]. Another agonist of PPARγ, rosiglitazone treatment
was shown to limit neutrophil inﬁltration, nitrotyrosine
formation and lipid peroxidation following experimental
pancreatitis in mice [49]. Rosiglitazone was also shownRaghu Vemuganti 3
to decrease matrix metalloproteinase (MMP)-9 expression,
T-cell activation, and TNFα and amyloid-A levels in diabetic
patients with coronary artery disease, thereby curtailing
the inﬂammatory response [50]. Both pioglitazone and
rosiglitazonewereshowntodecreaseinﬂammationinkidney
to prevent nephropathy resulting from diabetes and hyper-
tension [51]. In experimental animals, 15dPGJ2 was shown
to inhibit NF-κB activation and other proinﬂammatory
proteins like activating protein-1 (AP-1), iNOS, and ICAM1,
thereby decreasing oxidative stress to protect kidneys from
ischemic damage [51–53]. Upon activation, TZD pretreated
peripheral blood monocytes show decreased cytokine release
and altered inﬂammatory gene expression [42, 54]. It was
shown that PPARγ activation antagonizes transcription fac-
tors STAT, NF-κB, and AP1 by decreasing their DNAbinding
leading to decreased expression of the downstream genes
iNOS, MMP9, and scavenger receptor-A [41, 55, 56].
8. PPARγ ACTIVATION AND STROKE
Massive inﬂammation is a known precipitator of stroke-
induced brain damage [20, 21, 57]. Many anti-inﬂammatory
compounds including minocycline, curcumin, caﬀeic acid
phenyl ester and Brazilein can limit cerebral inﬂammation,
and thus ischemic neuronal death [58–61]. As brain damage
following focal ischemia is known to be mediated by many
synergistic mechanisms including edema, ionic imbalance,
apoptosis, oxidative stress, and ER stress, combination of
drugs that prevent some if not all these pathophysiological
changes might be needed to eﬃciently control ischemic
neuronal death.
Consistent with the known beneﬁts of PPARγ activation
in conditions of inﬂammation, several animal studies have
demonstrated the therapeutic potential of TZDs in improv-
ing postischemic functional outcome. As 2 TZDs rosiglita-
zone and pioglitazone are currently approved by FDA for
type-2 diabetes treatment and as the incidence of stroke and
stroke-induced brain damage are higher in type-2 diabetics,
these studies assume great importance [32, 62, 63]. Fol-
lowing transient focal ischemia in rodents, cerebral PPARγ
expression signiﬁcantly elevates, especially in the peri-infarct
area, and treatment with PPARγ agonists transrepress the
expression of many downstream proinﬂammatory genes
[64]. Furthermore, rosiglitazone or pioglitazone treatment
increases PPARγ translocation to the nucleus in neurons that
will be enhanced by RXR agonist retinoic acid [64, 65].
Both pretreatment as well as posttreatment with TZDs
was shown to induce neuroprotection after focal ischemia
[32, 66–69]. In addition, TZD treatment was observed to be
eﬀective irrespective of the route of administration. Postis-
chemic neuroprotection was observed following intraperi-
toneal (i.p.) injections, intracerebroventricular (i.c.v.) infu-
sion as well as feeding animals with chow enriched with
aT Z D[ 32, 66–68]. In adult rats and mice, pretreatment
with troglitazone, rosiglitazone, or pioglitazone (i.p.) prior
to ischemia was shown to decrease the infarct volume,
microglial activation, macrophage inﬁltration, and expres-
sion of proinﬂammatory genes cyclooxygenase-2 (COX2),
iNOS, and IL-1β mRNA in the ischemic hemisphere [32,
66, 68]. The rosiglitazone neuroprotection was observed to
be completely reversed by treating rats with GW9662 (a
speciﬁc PPARγ antagonist) indicating a direct involvement
of PPARγ [32]. Pioglitazone when infused i.c.v. for 5 days
priortoand2daysafterfocalischemiasigniﬁcantlyincreased
the sensory neurological scores and reduced edema and
infarct volume [67]. In another study, rats tube fed with
rosiglitazone for 7 days prior to and 3 days after transient
focal ischemia showed increased endothelial NO synthase
(eNOS) expression and neoangiogenesis leading to ischemic
tolerance [70]. Pioglitazone pretreatment was not observed
to be neuroprotective following permanent focal ischemia in
rats, suggesting that the beneﬁcial eﬀects of TZDs are limited
to reperfusion-induced damage [71]. Importantly, TZD-
induced neuroprotection was also observed in hypertensive
and diabetic rodents subjected to transient focal ischemia
[32].
9. PPAR ACTS TOGETHER WITH OTHER
TRANSCRIPTION FACTORS
The transrepression of inﬂammatory genes by PPAR acts in
cooperation with many other transcription factors includ-
ing NF-κB, AP-1, Egr1, and c/EBPβ, and by inhibiting
the ubiquitylation/degradation of corepressor proteins via
sumoylation [72]. Vascular inﬂammation was shown to be
controlled by the interaction of PPARγ and c/EBPβ by
negatively regulating the expression of inﬂammatory genes
like IL-6, IL1β,a n dT N F α [73]. This is made possible by
the presence of tandem repeats of c/EBPβ motif in the
PPARγ promoter region enabling transactivation of PPARγ
gene. The PPAR:RXR heterodimer complex also competes
with the coactivator complexes as well as interacts directly
with other transcription factors to regulate their function.
In addition, TZDs can have PPARγ-independent actions that
include mitochondrial dysfunction-related, stress-response,
increased astrocyte, glucose uptake and lactate production,
and modulation of the mitochondrial protein MitoNeet [74,
75].
10. EFFICACY OF PPARγ AGONISTS AFTER
FOCAL ISCHEMIA
Of the two FDA-approved TZDs, pioglitazone is known to
cross BBB more eﬃciently than rosiglitazone, but the aﬃnity
of pioglitazone to PPARγ is 10 times lower (Kd of ∼400nM)
than for rosiglitazone (Kd of ∼40nM) [1, 76]. In addition to
stimulating PPARγ, pioglitazone also functions as a partial
agonist of PPARα, whereas rosiglitazone functions as a pure
PPARγ agonist [13]. To make things complicated, recent
studies demonstrated that to induce the same degree of
neuroprotectionfollowingfocalischemiaorSCI,comparable
doses of pioglitazone and rosiglitazone are needed [32, 77].
11. NONINFLAMMATION-RELATED
NEUROPROTECTIVE ACTIONS OF TZDs
Although preventing inﬂammation seems to be the major
neuroprotective mechanism of PPAR agonists after stroke,4 PPAR Research
bothPPARγ andPPARαagonistswereshowntoinduceother
beneﬁcial eﬀects like reducing oxidative stress, increasing
endothelial relaxation, and preventing apoptosis in the
postischemic brain [63, 78, 79]. When oxidative stress
was induced in immortalized mouse hippocampal cells
by exposing to glutamate or hydrogen peroxide, PPARγ
agonists protected the cells from death [39]. Transient
focal ischemia is known to promote reactive oxygen species
(ROS) production and reduce glutathione levels (which
scavenge ROS) simultaneously [80]. This leads to enormous
oxidative stress and neuronal death. The cytosolic antioxi-
dant enzyme, endothelial copper/zinc-superoxide dismutase
(Cu/Zn-SOD) is known to decrease oxygen-free radicals to
mitigate eNOS inactivation [81]. Catalase, the other major
antioxidant enzyme which is very active in peroxisomes
of both neurons and glial cells [82, 83]p r o t e c t sc e l l sb y
quicklydegradinghydrogenperoxide.Neuronsareextremely
labile to oxidative damage and cellular stress is a known
inducer of both Cu/Zn-SOD and catalase expression to
counter the oxidative stress and to protect neurons following
focal ischemia. As the promoters of SOD and catalase genes
contain PPRE, they are directly upregulated when PPARγ is
activated [81, 84].
Recent studies from our laboratory showed that in nor-
motensive and hypertensive rodents subjected to transient
focalischemia,rosiglitazonetreatmentsigniﬁcantlyincreases
Cu/Zn-SOD and catalase activity in the peri-infarct region
whichmightberesponsiblefortheobservedneuroprotection
[32]. In addition, rosiglitazone also decreased COX-2 and
iNOS levels (indicating reduced production of ROS and
NO) in peri-infarct neurons [34]. It was also reported that
both pioglitazone and rosiglitazone signiﬁcantly prevent
glutathione depletion following focal ischemia in adult rats
[80].
As ROS promotes apoptosis and TZDs minimize ROS
formation, PPARγ activation was thought to prevent postis-
chemic apoptotic neuronal death [85, 86]. A recent study
showed that rosiglitazone treatment decreases caspase-3
levels leading to reduced apoptotic cell death following focal
ischemia [87]. This seems to be a direct PPARγ downstream
eﬀect as pretreating animals with the PPARγ antagonist
GW9662preventedtheantiapoptoticactionsofrosiglitazone
[87]. Pioglitazone treatment was also shown to promote the
expression of antiapoptotic gene Bcl2 while simultaneously
preventing the expression of proapoptotic gene Bax in the
peri-infarct regions of brain following focal ischemia [13,
88].
12. PPARγ AGONIST-INDUCED NEUROPROTECTION
IN HUMAN STROKE SUBJECTS
A recent clinical trial, named the Prospective Piogli-
tazone Clinical Trialin Macrovascular events (proactive)
started evaluating if pioglitazone treatment can prevent
the macrovascularevents in type-2 diabetes [89, 90]. This
extensive study evaluated 5, 238 patients in 19 countries.
In particular, one prespeciﬁed subgroup analysis evaluated
the eﬀect of pioglitazone in patients with (n = 984) or
without (n = 2867) a history of stroke and observed a 16%
relative risk reduction in the pioglitazone group compared
to placebo group [91]. In addition, within the group
of patients with a previous stroke, pioglitazone therapy
decreased the risk of recurrent stroke by 47% compared
to placebo over 3 years. But pioglitazone had no eﬀect on
decreasing ﬁrst strokes over this period. While this shows an
encouraging trend for stroke patients, serious heart failure
was observed to be increased signiﬁcantly in the piogli-
tazone group compared to placebo group. The complete
details and results of the proactive trial can be viewed
at the website http://www.proactive-results.com/index.htm.
Yki-J¨ arvinen [92] commented critically on this trial that
pioglitazone group showed increased edema and increased
incidence of pneumonia. Furthermore, the weight gain was
4kg greater in the pioglitazone over placebo group which is
undesirable. A recent study also showed that pioglitazone or
rosiglitazone therapy signiﬁcantly enhanced the functional
recovery in a group of 30 type-2 diabetes patients admitted
in the hospital for acute stroke rehabilitation [93].
13. BENEFICIAL EFFECT OF PPARγ ACTIVATION
IN OTHER CNS INJURIES
PPARγ activation by TZDs was shown to prevent inﬂam-
mation and neuronal death in several in vitro and in vivo
models of CNS diseases [40, 94–97]. In patients suﬀering
with Alzheimer disease, PPARγ activation was shown to
prevent TNFα and iNOS expression in macrophages, thus
limiting the inﬂammation and cognitive impairment [40,
98]. TZDs were known to signiﬁcantly reduce the dopamin-
ergic neuronal loss leading to improved neurological status
in Parkinson’s disease [99]. Using the rodent model of multi-
ple sclerosis (experimental autoimmune encephalomyelitis),
PPARγ agonist treatment was shown to suppress activation
of T-cells, microglia, and macrophages thus decreasing
proinﬂammatory factor formation leading to improved neu-
rological outcome [94, 96, 100]. Pioglitazone oral treatment
was reported to decrease the microglial activation, motor
neuron loss, and muscular atrophy in transgenic mice over-
expressing SOD1-G93A (an animal model of Amyotrophic
lateral sclerosis) with pioglitazone [101, 102]. These mice
also showed increased anti-inﬂammatory gene expression
upon treatment with pioglitazone [101]. More recently, two
studies showed the beneﬁcial eﬀects of treating rodents
with PPARγ agonists following spinal cord injury (SCI) [77,
103]. Our laboratory demonstrated that both rosiglitazone
and pioglitazone decreases inﬂammatory cell activation and
inﬂammatory gene expression leading to smaller lesion size,
better motor recovery, and less neuropathic pain after SCI in
rats [77]. Importantly, we showed that pretreating rats with
the PPARγ antagonist GW9662 prevents many beneﬁcial
eﬀects of TZDs following SCI indicating a direct mediation
of PPARγ in promoting post-SCI neuronal recovery [77].
14. PPARγ-INDEPENDENT NEUROPROTECTIVE
ACTIONS OF PPARγ AGONISTS
While the anti-inﬂammatory and neuroprotective actions
of PPARγ agonists are expected to be mediated via PPARγRaghu Vemuganti 5
stimulation, some studies suggested that PPARγ agonists
also induce many beneﬁcial eﬀects via PPARγ-independent
mechanisms as well. 15dPGJ2 was shown to prevent
astroglial and microglial activation by bacterial endotox-
ins without involving PPARγ [12]. The anti-inﬂammatory
action of 15dPGJ2 was shown to be mediated by binding
to and inactivating inhibitor of kappa B (IκB) kinase
and by alkylating the p50/p65 dimers and thus preventing
the activation of NF-κB without involving PPARγ [52,
55]. Following focal ischemia, the proinﬂammatory actions
of the cytokine IL6 are known to be mediated by the
activation of IL6 receptor-associated Janus kinases (JAKs)
and their downstream STAT family of transcription factors
[25]. Suppressor of cytokine signalling (SOCS) proteins
act as negative feedback regulators and inhibit JAK and
STATphosphorylation,thuspreventingtheupregulationand
binding of cytokines to their receptors after an acute CNS
insult [32, 104]. Recent studies from our group and others
demonstrated that rosiglitazone and 15dPGJ2 induce SOCS3
expression and prevent JAK2 and STAT3 phosphorylation
[32, 105]. Thus the neuroprotective actions of PPARγ
agonists might also mediated by direct actions on JAK-
STAT-SOCS pathway. Our recent studies also showed that
pioglitazone treatment after SCI induces the heat shock
protein (HSP)-27, HSP70, and HSP32 (hemeoxygenase-1)
which induce neuroprotection [104].
15. ACTIVATION OF OTHER PPAR ISOFORMS ALSO
INDUCES NEUROPROTECTION
In addition to PPARγ,P P A R α,a n dP P A R β/δ,a c t i v a t i o n
was also shown to signiﬁcantly prevent inﬂammation and
induce protection after injury to CNS as well as periph-
eral organs. PPARα activation is known to induce neu-
roprotection after focal ischemia [36, 78]. PPARα plays a
very important regulatory role in response to injury or
stress. As PPARα is known to be expressed when mono-
cytes diﬀerentiate into macrophages, it inﬂuences postin-
jury inﬂammatory reactions [105]. Furthermore, agonist-
induced activation of PPARα increases IκBα levels lead-
ing to an inhibition of NF-κB[ 106]. PPARα activation
decreases the level of proatherosclerotic ﬁbrinogen and C-
reactive protein in experimental animals [107]. Fenoﬁbrate,
a potent exogenous agonist of PPARα, inhibits left ven-
t r i c u l a rh y p e r t r o p h yb ys t i m u l a t i n gf r e ef a t t ya c i du p t a k e
and β-oxidation [63]. Fenoﬁbrate pretreatment reduces the
susceptibility of mice deﬁcient in apolipoprotein-E, and
decreases the infarct volume in wild type mice subjected
t of o c a lc e r e b r a li s c h e m i a[ 78]. Poststroke neuroprotection
induced by PPARα agonists will be mediated by both
cerebral and vascular mechanisms. Fenoﬁbrate treatment
is known to decrease vascular endothelial dysfunction and
improves endothelium-dependent vasodilatation in patients
with hypertriglyceridemia [91]. Recent studies showed that
aP P A R α/γ dual agonist bezaﬁbrate decreases anaerobic
metabolism and there by prevents death in gerbils subjected
to global cerebral ischemia [108]. Fibrates are also reported
to prevent secondary neuronal death by oxidative stress by
enhancing the expression of antioxidant enzyme, Cu/Zn-
SOD, and by decreasing vascular cell adhesion molecule-
1 expression in CNS blood vessels, possibly by inhibiting
the NF-κBp a t h w a y[ 98, 109]. The functional signiﬁcance
of PPARβ/δ in preventing CNS inﬂammation is not stud-
ied in detail. However, the PPARβ/δ agonists L-165041,
and GW501516 were shown to signiﬁcantly decrease focal
ischemia-induced infarction and brain damage in adult rats
[110]. In rodents, PPARβ/δ agonists were also demonstrated
to prevent striatal dopamine loss after 1-methyl 4-phenyl
1,2,3,6-tetrahydropyridine administration [110]. PPARβ/δ
agonist GW0742 was reported to inhibit lipopolysaccharide-
induced TNFα secretion in cardiomyocytes [111].
16. CONCLUSIONS
Despite decades of research, no therapies that can prevent
the secondary neuronal death and the ensuing neurological
deﬁcits after stroke are currently available. Many patholog-
ical mechanisms including inﬂammation, ionic imbalance,
excitotoxicity, edema, oxidative stress, and ER stress syner-
gistically promote the poststroke secondary neuronal death.
Hence therapeutics that simultaneously targets several of
these mechanisms with minimal side eﬀects is extremely
useful in stroke therapy. PPARγ agonists like rosiglitazone
and pioglitazone are FDA approved and being prescribed to
millions of type-2 diabetics allover the world. The beneﬁt of
these compounds seems to be their potential to inﬂuence
multiple molecular mechanisms. For example, they are
known to minimize the harmful events like inﬂammation
andoxidativestressatthesametimepromotetheantioxidant
defence and protein chaperones. Hence PPARγ agonists
might be an important class of drugs for use in stroke
therapy. The beneﬁts of PPARγ agonist treatment was also
observed in other acute CNS injuries like SCIas well as
chronic neurodegenerative disorders like multiple sclerosis,
Alzheimer’s disease, and Parkinson’s disease increasing the
promise of these compounds as future neuroprotective
therapies.
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